TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics has made significant strides in FY25, transitioning from an early-stage business to an emerging global diagnostics company. The company has expanded its distribution partnerships, notably with Henry Schein and PHASE Scientific, and has secured reimbursement for FebriDx on the U.S. Medicare fee schedule. A successful CLIA waiver trial for FebriDx has been completed, with the application submitted to the FDA, potentially expanding the U.S. market significantly. A new distribution agreement with PHASE Scientific could be worth up to US$317 million, marking a major milestone for Lumos. The company remains well-funded, with a focus on disciplined execution and expanding its product’s clinical use, supported by BARDA.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, point-of-care diagnostic technologies, offering customized assay development and manufacturing services to aid healthcare professionals in diagnosing and managing medical conditions. The company is focused on the global commercialization of its flagship product, FebriDx, and has a growing market presence, particularly in the U.S.
Average Trading Volume: 6,424,343
Technical Sentiment Signal: Buy
Current Market Cap: A$184.7M
See more data about LDX stock on TipRanks’ Stock Analysis page.